DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Reclast (Zoledronic Acid) - Summary

 
 



RECLAST SUMMARY

Reclast contains zoledronic acid, a bisphosphonic acid which is an inhibitor of osteoclastic bone resorption.

Reclast (zoledronic acid) is indicated for the following:

Postmenopausal Osteoporosis

      Reclast is indicated for treatment of osteoporosis in postmenopausal women. In postmenopausal women with osteoporosis, Reclast reduces the incidence of fractures (hip, vertebral and non-vertebral osteoporosis-related fractures) [ see Clinical Studies (14 .1)].

Paget's Disease of Bone

Reclast is indicated for treatment of Paget's disease of bone in men and women. Treatment is indicated in patients with Paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [ see Clinical Studies (14 . 2 ) ].


See all Reclast indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Reclast (Zoledronic Acid)

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. [2014]
myeloma... CONCLUSIONS: Denosumab was more effective in delaying or preventing SREs in

Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. [2013]
1 infusion of zoledronic acid... CONCLUSIONS: In this post hoc analysis based on postrandomization subgroups,

Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer. [2013]
lung cancer (NSCLC) with asymptomatic bone metastases (BMs)... CONCLUSIONS: Treatment with ZA and/or Sr-89 significantly extended the time to

Fracture risk and zoledronic acid therapy in men with osteoporosis. [2012]
osteoporosis... CONCLUSIONS: Zoledronic acid treatment was associated with a significantly

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. [2012]
across three pivotal studies... CONCLUSION: Denosumab was superior to zoledronic acid in preventing SRE with

more studies >>

Clinical Trials Related to Reclast (Zoledronic Acid)

Impact on Reducing the Incidence of Low Serum Calcium by Providing Educational Materials on the Need to Take Daily Supplemental Calcium and Vitamin D to Patients With Paget's Disease Treated With Reclast® [Completed]
This study will evaluate the impact of investigator and patient education and educational materials to foster calcium and vitamin D supplementation to mitigate the potential for hypocalcemia post Reclast® administration in patients with Paget's disease of bone.

PET Scanning to Evaluate Zoledronate Efficacy in Metastatic Prostate Cancer [Active, not recruiting]
The primary goal for this trial is to assess the change in PET scans with the administration of zoledronate (bisphosphonate) therapy in patients with metastatic prostate cancer. It has been established that zoledronate therapy may play a role in delaying and reducing the incidence of skeletal events. Researchers propose to evaluate the change in the uptake value of FMAU PET scan after the zoledronate therapy. It has been demonstrated that FMAU PET scans can successfully demonstrate and detect bony metastatic sites in prostate cancer. In addition, investigators would like to evaluate the change in the level of the prostate-specific antigen (PSA) in the patient as well as outcome of bone scans.

The Use of Zoledronic Acid to Complex Regional Pain Syndrome [Not yet recruiting]

Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer [Terminated]
The overall purpose of this research is to evaluate the safety and side effects of zoledronic acid (also known as Zometa) in patients before they have surgery to remove the cancer.

Zoledronic Acid Administration in Acute Spinal Cord Injury [Completed]
In subjects with acute SCI: To compare the effects of parenteral zoledronic acid therapy on preservation of regional and total skeletal mass (DXA). Hypothesis: Zoledronic acid will dramatically diminish bone loss in persons with acute SCI, as evidenced by serial densitometry determinations (DXA).

more trials >>

Reports of Suspected Reclast (Zoledronic Acid) Side Effects

Death (377)Pain (226)Arthralgia (210)Femur Fracture (154)Fall (153)Headache (137)Pain in Extremity (133)Nausea (121)Pyrexia (114)Myalgia (113)more >>


Page last updated: 2014-12-01

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017